Compare RLX Technology Inc (RLX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Twist Bioscience Corp — how do they compare? RLX Technology Inc trades at $2.03 (market cap $2.52B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 2.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RLX | TWST | |
|---|---|---|
Market Cap | $2.52B | $5.45B |
Sector | Technology | Health |
52-Week High | $2.73 | $102.88 |
52-Week Low | $1.79 | $24.16 |
Enterprise Value | $1.15B | $5.37B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $2.06, up 0.49% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 net income of $921.87M and a net margin of 22.47%. Recent news highlights the company's cash-rich, debt-free position and its positioning in the growing global vaping market.
The outlook is mixed; strong fundamentals and market growth potential are offset by consecutive earnings misses and a single analyst's hold rating. Key risks include regulatory scrutiny in the vaping industry and execution challenges in international expansion. The stock presents a speculative opportunity for investors comfortable with sector-specific regulatory risks.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
